Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Summary

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.

Timeline

Start

2022-12-29

Primary completion

2025-05-08

Completion

2025-05-08

Outcome

Met primary endpoint

Stopped (Business): “Sponsor business decision, not related to safety concerns.”

release “A Phase 2 study of daxdilimab in adult patients with moderate-to-severe primary discoid lupus erythematosus (DLE) is complete. The study met the primary endpoint” amgen.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daxdilimab	Monoclonal antibody	—	Subcutaneous

Indications